Loading
Life sciences · Journal article
Cancer Cell International · August 13, 2026
Raises a question worth testing. It does not answer one.
This review synthesizes evidence that VAP-1 (AOC3) is aberrantly expressed across multiple cancers and correlates with progression and survival. Preclinical data suggest VAP-1 inhibition may suppress angiogenesis and immunosuppression and synergize with checkpoint inhibitors, while VAP-1-targeted imaging may enable theranostic applications. However, no clinical trial results, effect sizes, or head-to-head comparisons are provided; the work outlines a research agenda rather than establishes clinical efficacy.
Narrative review. Patients with gliomas, breast, colorectal, ovarian, gastric, and thyroid cancers; preclinical tumor models..
Elevated tissue VAP-1 levels associated with aggressive behavior and unfavorable survival in gliomas and breast, colorectal, and ovarian cancers Altered circulating VAP-1 levels in gastric and thyroid cancers may have adjunctive diagnostic relevance alongside conventional biomarkers Preclinical studies document VAP-1 inhibition suppresses angiogenesis, reduces immunosuppressive myeloid cell infiltration, and restores antitumor immunity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies VAP-1 as a candidate biomarker and therapeutic target across multiple cancers, but clinical translation remains at an early stage. Clinicians should await primary trial data before considering VAP-1 inhibition or VAP-1-targeted imaging in routine practice.
This is a narrative review synthesizing preclinical and observational evidence on VAP-1 biology in cancer; it raises translational questions and proposes therapeutic targets but does not report primary trial data, effect sizes, or clinical outcome comparisons.
As stated by the source record.
This review identifies VAP-1 as a candidate biomarker and therapeutic target across multiple cancers, but clinical translation remains at an early stage. Clinicians should await primary trial data before considering VAP-1 inhibition or VAP-1-targeted imaging in routine practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Vascular adhesion protein-1 (VAP-1), also known as amine oxidase copper-containing 3 (AOC3), is a multifunctional molecule with dual adhesive and enzymatic activities, and can regulate leukocyte trafficking, redox signaling, and stromal interactions within the tumor microenvironment. Evidence from both experimental and clinical investigations has demonstrated the aberrant expression of VAP-1 in a wide range of cancers and its correlation with tumor progression and outcomes. Elevated tissue levels of VAP-1 are generally associated with aggressive behavior and unfavorable survival in gliomas and breast, colorectal, and ovarian cancers, whereas altered circulating levels in gastric and thyroid cancers may have adjunctive diagnostic relevance when interpreted alongside conventional biomarkers, imaging findings, and clinicopathological features. Preclinical studies have documented the therapeutic advantages of VAP-1, as the inhibition of its enzymatic activities can suppress angiogenesis, reduce the infiltration of immunosuppressive myeloid cells, and restore antitumor immunity, with synergy observed in combination with immune checkpoint inhibitors. Moreover, novel molecular imaging strategies using VAP-1-specific ligands may support theranostic applications, offering opportunities for patient stratification and real-time assessment of therapeutic responses in selected contexts. This review gathers evidence on the involvement of VAP-1 in the pathogenesis of cancers and its diagnostic and therapeutic applications. The integration of data from basic and translational studies will underscore both the opportunities and challenges of targeting VAP-1 and guide future studies of the applications of targeting VAP-1 in the clinical setting.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.